Background
==========

Multimodal treatment is the standard of care for locally advanced adenocarcinomas of the esophagus or stomach since several randomized trials and meta-analyses have shown a prognostic benefit for (peri-) preoperative therapy versus surgery alone \[[@B1]-[@B4]\]. For patients who received multimodal treatment it is widely accepted that responding patients have a significantly better outcome than nonresponding patients \[[@B5]-[@B8]\]. However, depending on the therapy regimen applied, only 25-50% of patients respond to (peri-) preoperative treatment. Until now no molecular markers are available to predict response or survival in clinical routine and to tailor treatment individually. Despite the current guidelines favoring a multimodal treatment for locally advanced tumors, a relevant number of patients are still resected without preoperative treatment due to favorable tumor categories, differing local standards, individual risk factors or patients' choice.

Simple pretherapeutically available cliniocopathological factors like tumor localization, grading, content of signet ring cells and Laurén classification have been found to be associated with prognosis in patients with and without preoperative treatment in several studies \[[@B9]-[@B14]\]. So far, however these factors are not routinely used to tailor treatment or to stratify groups within clinical trials. Several studies on molecular and genetic prognostic and/or predictive markers in patients with gastric cancer have been published, but none of them (apart from HER-2 \[[@B15]\] in the palliative setting) gained clinical relevance \[[@B16],[@B17]\]. Aside from tumor related factors, constitutional factors such as genetic polymorphisms are accepted to be associated with response and prognosis in adenocarcinomas of esophagus or stomach \[[@B18]-[@B21]\]. Most data exist for genetic polymorphisms being involved in pharmacodynamics and drug metabolism. Our own data on constitutional polymorphisms have shown to a large extent that the examined constitutional variants were associated rather with prognosis, than with response to preoperative treatment \[[@B22],[@B23]\]. Only a few studies have investigated constitutional factors with the goal to clarify whether these factors are only relevant in the presence of chemotherapy or if they are prognostic factors irrespective of preoperative treatment \[[@B22]\].

Methylentetrahydrofolate reductase (MTHFR) plays a major role in the folate metabolism and consequently could be an important factor for the efficacy of a treatment with 5-fluorouracil (5-FU) \[[@B24]-[@B27]\].

The MTHFR single nucleotide polymorphism (SNP) C677T (rs 1801133) has shown to be associated with prognosis in gastric cancer patients in several studies \[[@B23],[@B28],[@B29]\], however results are still conflicting \[[@B30]\] and the clinical relevance of this SNP has to be reproduced before clinical consequences can be drawn.

Another SNP in the MTHFR gene (A1298C) (rs 1801131) has also been investigated in several studies but results are less convincing than for C677T \[[@B31],[@B32]\]. A recent study of our group found a significant association of this MTHFR gene A1298C polymorphism with prognosis in 258 neoadjuvantly treated esophagogastric adenocarcinomas \[[@B23]\].

In this study we focused on these two polymorphisms in the MTHFR gene to confirm the prognostic significance of the respective MTHFR gene polymorphisms in a larger group of esophagogastric cancer patients with neoadjuvant treatment as well as to test whether these polymorphisms can be used as a predictor for response to neoadjuvant chemotherapy. Additionally we wanted to test their relevance in a group of patients without perioperative chemotherapy.

Methods
=======

569 patients with histologically proven adenocarcinoma of the esophagus (AEG I), esophagogastric junction (AEG II, III) or stomach (GC) were included in the study. Patients were treated in the Klinikum rechts der Isar, Munich from 1994--2005 (n = 361) or the University Hospital Heidelberg, Surgical Department from 2007--2010 (n = 235), 27 patients were excluded due to non-operative treatment. 369 patients received neoadjuvant chemotherapy followed by surgery, while 200 patients were resected without preoperative treatment (Figure [1](#F1){ref-type="fig"}).
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It is of note that for 244 of the 369 neoadjuvantly treated patients the results with shorter follow-up have been reported recently for both analyzed polymorphisms \[[@B23]\].

The study was approved by the ethical committee of the University of Heidelberg and of the Technical University of Munich and written informed consent was obtained from all patients.

Data assessment
---------------

Demographic data, primary tumor localization, grading, type of resection, Lauren's subtype, ypTNM- and R-category, data on clinical and histopathological response as well as perioperative complications and mortality were documented prospectively in a database containing all patients with carcinoma of the esophagus or stomach in the two centers.

Genotyping
----------

Blood was collected from patients before surgery. DNA from blood was isolated with Qiagen mini-preparation kits and genotyped for the two polymorphisms in the MTHFR gene (C677T and A1298C). Genotyping was performed using KASPar chemistry, a competitive allele-specific PCR genotyping system (<http://www.lgcgenomics.com>) according to manufacturer's instructions. The PCR was carried out in plates of 96 wells, in a total reaction volume of 8 μl using 10 ng of genomic DNA, 2 μl 2X KASPar reaction mix and 0.11 μl of the assay mix. The PCR conditions were: an initial denaturation at 94°C for 15 minutes, 10 touch-down cycles of 20 s at 94°C and 60 s at 61-55°C (temperature decrement by 0.6°C per cycle) and additional 25--30 cycles at 20 s at 94°C and 60 s at 55°C. Genotypes in amplified products were determined by differences in VIC and FAM fluorescent level in plate read operation on ABI PRISM 7900HT (Applied Biosystems, Foster City, CA) using SDS 2.2 Software. Post operation data were transferred to Microsoft Excel files and converted into genotype information. The genotype quality control was validated through DNA sequencing in 5% of the samples.

Chemotherapy
------------

369 patients were treated with neoadjuvant chemotherapy: Munich (n = 247): OLF/PLF regimen: either oxaliplatin 85 mg/m^2^ or cisplatin 50 mg/m^2^ on days 1,15,29 and folinic acid (500 mg/m^2^ over 2 h) plus fluorouracil (2000 mg/m^2^) on days 1,8,15,22,29 and 36, all repeated on day 49, for patients with a good health status additionally paclitaxel (80 mg/m^2^) on days 0, 14 and 28) was given \[[@B33]\]. Heidelberg (n = 122): EOX-regimen: epirubicin 50 mg/m2 (day 1), oxaliplatin 130 mg/m2 (day 1), and capecitabin 1,250 mg/m2 (days 1--21), all repeated on day 22., PLF (see above), and FLOT: oxaliplatin 85 mg/m2 (day 1), docetaxel 50 mg/m2 (day 1), folinacid 200 mg/m2 (day 1), and 5-fluoruracil 2,600 mg/m2 (day 1), all repeated on day 15 \[[@B9]\].

Surgery
-------

The type of surgery was performed according to the tumor localization and local standards: for patients with AEG I either an abominothoracic approach with intrathoracic anastomosis (Ivor Lewis procedure) \[[@B34]\] or a transhiatal esophagectomy \[[@B35]\], both including an abdominal D-2 lymphadenectomy, for patients with adenocarcinoma of the esophagogastric junction (AEG II, III) a transhiatal gastrectomy, in some cases an Ivor lewis procedure \[[@B36]\] or a transhiatal esophagectomy \[[@B35]\] was performed. Patients with gastric cancer received a total gastrectomy or subtotal gastrectomy \[[@B37]\] if an adequate proximal resection margin was possible. Both procedures included a D2-lymphadenectomy.

Response to chemotherapy
------------------------

Clinical response was assessed after chemotherapy and before surgery comparing pre- and posttherapeutic computed tomography imaging and endoscopy. The evaluation was done by an interdisciplinary tumor board of the Klinikum rechts der Isar, Munich or by the Surgical Department of the University of Heidelberg. Criteria for response were a decrease of the maximal transversal tumor diameter of \>50% in CT and an estimated decrease in endoluminal tumor size of \>75% in endoscopy. Patients with minor response, no change or progressive disease were classified as nonresponder \[[@B38]-[@B40]\].

Histopathological response was assessed according to the Becker regression score \[[@B5],[@B41]\]: tumor regression grade (TRG) 1a (complete regression) and 1b (\<10% residual tumor) were classified as histopathological response, TRG 2 (10-50% residual tumor) and 3 (\>50% residual tumor) as nonresponse.

Follow-up
---------

Follow-up was done according to the local guidelines. Patients who were not followed in one of the two centers were contacted by phone to obtain follow-up data. Median time of follow-up of the surviving patients was 41.1+/− 25.8 months.

Statistical analysis
--------------------

For statistical analysis we used SPSS 20.0 (IBM Inc. Chicago). Quantitative data is presented as mean +/− standard deviation. Survival curves were estimated by the Kaplan-Meier method and presented in months from time of diagnosis to death. Differences in survival times were calculated using the log-rank test. For univariate and multivariate analysis we used the Cox proportional hazard model. For correlation between different parameters we used the Chi-square-test (two-sided) where appropriate. P-values \<0.05 were considered as statistically significant.

Results
=======

230 patients out of 569 have died. Median survival of the entire population was 66.0 months. Median survival of patients treated in Munich was 72.8 months, in Heidelberg 85.6 months.

Patients' characteristics including survival times are presented in Table [1](#T1){ref-type="table"}.

###### 

Patients' characteristics and survival times according to clinicopathological factors

  **Characteristics**                                   **n**   **%**   **Median (months)**   **3-Y-S (%)**   **5-Y-S (%)**   **p**
  ----------------------------------- ----------------- ------- ------- --------------------- --------------- --------------- ---------
  a: All patients                                                                                                              
  **Sex**                             Male              431     75.7    66.0                  60.8            52.6            0.637
                                      Female            138     24.3    66.0                  57.0            52.7             
  **Localization**                    AEG               351     61.7    74.2                  60.4            52.4            0.81
  **UICC 7th edition**                Gastric cancer    212     37.3    62.2                  58.7            52.3             
  **Localization**                    AEG I             143     25.1    108.0                 63.0            55.5            0.288
  **UICC 6th edition**                AEG II/III + GC   426     74.9    64.1                  58.9            51.8             
  **Laurén**                          intestinal        320     56.2    78.8                  65.1            57.2            0.029
                                      non-intestinal    234     41.1    47.1                  54.8            48.2             
  **Grading**                         low grade         166     29.2    108.0                 69.3            64.7            0.012
                                      high grade        395     69.4    54.1                  56.4            47.8             
  **pT**                              pT0               38      6.7     n.r.                  85.6            76.4            \<0.001
                                      pT1               52      9.1     n.r.                  83.5            83.5             
                                      pT2               276     48.5    85.6                  68.7            62.5             
                                      pT3               184     32.2    26.7                  37.4            25.4             
                                      pT4               19      3.3     14.2                  5.3             0.0              
  **pN**                              pN0               242     42.5    101.9                 76.8            69.6            \<0.001
                                      pN1               201     35.3    33.3                  48.2            39.4             
                                      pN2               74      13      26.3                  41.3            34.6             
                                      pN3               28      4.9     18.9                  25.4            25.4             
                                      pNx               24      4.2     n.r.                  78.5            78.5             
  **pM**                              pM0               525     92.3    72.8                  62.0            54.6            0.001
                                      pM1               44      7.7     23.6                  36.3            32.2             
  **R**                               R0                476     83.7    74.2                  64.7            56.7            \<0.001
                                      R1/R2             93      16.3    20.3                  34.2            32.2             
  **Neoadjuvant chemotherapy**        yes               369     64.9    74.2                  61.5            52.6            0.157
                                      no                200     35.1    62.2                  56.8            53.1             
  **Characteristics**                                   **n**   **%**   **Median (months)**   **3-Y-S (%)**   **5-Y-S (%)**   **p**
  b: Neoadjuvantly treated patients                                                                                            
  **Sex**                             Male              309     83.7    78.8                  63.2            53.7            0.253
                                      Female            60      16.3    48.6                  53.0            46.9             
  **Localization**                    AEG               287     77.8    78.8                  63.4            54.4            0.259
  **UICC 7th edition**                Gastric cancer    82      22.2    42.5                  55.7            46.3             
  **Localization**                    AEG I             139     37.7    108.0                 62.8            55.3            0.653
  **UICC 6th edition**                AEG II/III + GC   230     62.3    66.0                  61.0            51.1             
  **Laurén**                          Intestinal        220     59.6    108.0                 67.3            58.7            0.014
                                      Non-intestinal    140     37.9    40.5                  54.4            44.6             
  **Grading**                         Low grade         109     29.5    108.0                 73.0            68.2            0.008
                                      High grade        254     68.8    47.1                  56.8            45.3             
  **pT**                              pT0               38      10.3    n.r.                  85.6            76.4            \<0.001
                                      pT1               35      9.5     n.r.                  83.2            83.2             
                                      pT2               169     45.8    101.9                 68.7            60.3             
                                      pT3               116     31.4    26.9                  39.5            25.2             
                                      pT4               11      3.0     14.2                  0.0             0.0              
  **pN**                              pN0               157     42.5    108.0                 77.4            69.3            \<0.001
                                      pN1               142     38.5    34.0                  49.0            38.6             
                                      pN2               39      10.6    29.1                  44.1            31.6             
                                      pN3               17      4.6     18.9                  38.5            38.5             
                                      pNx               14      3.8     n.r.                  77.9            77.9             
  **pM**                              pM0               328     88.9    82.7                  65.1            55.6            \<0.001
                                      pM1               41      11.1    23.6                  33.4            28.6             
  **R**                               R0                291     78.9    n.r.                  69.0            58.4            \<0.001
                                      R1/R2             78      21.1    20.3                  32.7            30.4             
  **Clinical response**               Responder         105     28.5    39.2                  82.6            74.2            \<0.001
                                      Nonresponder      263     71.3    108.0                 52.4            42.8             
  **TRG**                             1a,1b             104     28.2    n.r.                  83.8            77.4            \<0.001
                                      2,3               263     71.3    39.2                  52.5            42.1             
  **Characteristics**                                   **n**   **%**   **Median (months)**   **3-Y-S (%)**   **5-Y-S (%)**   **p**
  c: Primarily resected patients                                                                                               
  **Sex**                             Male              122     61.0    62.2                  54.6            50.1            0.318
                                      Female            78      39.0    66.0                  60.5            57.5             
  **Localization**                    AEG               64      32.0    32.6                  46.9            44.3            0.049
  **UICC 7th edition**                Gastric cancer    131     65.5    64.1                  60.7            56.4             
  **Localization**                    AEG I             4       2.0     n.r.                  75.0            75.0            0.619
  **UICC 6th edition**                AEG II/III + GC   196     98.0    62.2                  56.5            52.9             
  **Laurén**                          Intestinal        100     50.0    62.2                  59.8            53.4            0.807
                                      Non-intestinal    94      47.0    64.1                  55.7            54.0             
  **Grading**                         Low grade         57      28.5    62.2                  61.5            55.9            0.526
                                      High grade        141     70.5    64.1                  55.8            52.2             
  **pT**                              pT0               0       0.0                                                           \<0.001
                                      pT1               17      8.5     n.r.                  86.5            86.5             
                                      pT2               107     53.5    85.6                  68.5            65.4             
                                      pT3               68      34.0    25.8                  33.2            26.6             
                                      pT4               8       4.0     10.3                  12.5            12.5             
  **pN**                              pN0               85      42.5    85.6                  76.0            70.2            \<0.001
                                      pN1               59      29.5    32.0                  45.4            41.6             
                                      pN2               35      17.5    21.7                  37.9            28.4             
                                      pN3               11      5.5     16.1                  9.1             9.1              
                                      pNx               10      5.0     n.r.                  78.8            78.8             
  **pM**                              pM0               197     98.5    62.2                  56.6            52.9            0.684
                                      pM1               3       1.5     n.r.                  66.7            66.7             
  **R**                               R0                185     92.5    64.1                  57.8            53.9            0.144
                                      R1/R2             15      7.5     18.1                  44.4            0.0              

MS = median survival, 3-Y-S = 3-Year-Survival, 5-Y-S = 5-Year-Survival, AEG = adenocarcinoma of the esophagogastric junction, TRG = tumor regression grade, n.r. = not reached.

Relevant prognostic factors were Laurén's type (p = 0.029), Grading (p = 0.012), (y)pT-category (p \< 0.0000001), (y)pN-category (p \< 0.0000001), (y)pM-category (p = 0.001), R-category (p \< 0.0000001), additionally clinical response (p \< 0.0000001) and histopathological response (p \< 0.0000001) for patients treated with neoadjuvant chemotherapy.

Genotype frequencies and correlation with clinicopathological factors
---------------------------------------------------------------------

The genotype frequencies were in accordance with the Hardy-Weinberg-equilibrium. Frequencies of the individual genotypes are presented in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. No individual genotype showed any statistical correlation with a clinicopathological factor listed above, also if analyzed separately for the respective tumor entities (AEG versus GC) and treatment groups (primary resection versus neoadjuvant treatment).

###### 

Genotype frequencies: MTHFR C677T

                                                   **     MTHFR C677T**                              **p**
  ------------------------------ ----------------- ---------------------- ------------- ------------ -------
  **All patients**                                 254 (44.6%)            262 (46.0%)   53 (9.3%)     
  **Status**                     Alive             143 (42.2%)            162 (47.8%)   34 (10%)     0.342
                                 Dead              111 (48.3%)            100 (43.5%)   19 (8.3%)     
  **Sex**                        Male              189 (43.9%)            202 (46.9%)   40 (9.3%)    0.775
                                 Female            65 (47.1%)             60 (43.5%)    13 (9.4%)     
  **Localization**               AEG               153 (43.6%)            169 (48.1%)   29 (8.3%)    0.337
  **UICC 7th edtiion**           Gastric cancer    99 (46.7%)             90 (42.5%)    23 (10.8%)    
  **Localization**               AEG I             63 (44.1%)             68 (47.6%)    12 (8.4%)    0.868
  **UICC 6th edition**           AEG II/III + GC   191 (44.8%)            194 (45.5%)   41 (9.6%)     
  **Laurén**                     Intestinal        137 (42.8%)            151 (47.2%)   32 (10.0%)   0.731
                                 Non-intestinal    107 (45.7%)            107 (45.7%)   20 (8.5%)     
  **Grading**                    Low grade         74 (44.6%)             75 (45.2%)    17 (10.2%)   0.89
                                 High grade        174 (44.1%)            185 (46.8%)   36 (9.1%)     
  **pT**                         pT0               14 (36.8%)             21 (55.3%)    3 (7.9%)     0.751
                                 pT1               20 (38.5%)             28 (53.8%)    4 (7.7%)      
                                 pT2               134 (48.6%)            118 (42.8%)   24 (8.7%)     
                                 pT3               78 (42.4%)             86 (46.7%)    20 (10.9%)    
                                 pT4               8 (42.1%)              9 (47.4%)     2 (10.5%)     
  **pN**                         pN0               109 (45.0%)            115 (47.5%)   18 (7.4%)    0.642
                                 pN1               93 (46.3%)             88 (43.8%)    20 (10.0%)    
                                 pN2               31 (41.9%)             33 (44.6%)    10 (13.5%)    
                                 pN3               12 (42.9%)             15 (53.6%)    1 (3.6%)      
                                 pNx               9 (37.5%)              11 (45.8%)    4 (16.7%)     
  **pM**                         pM0               236 (45.0%)            243 (46.3%)   46 (8.8%)    0.292
                                 pM1               18 (40.9%)             19 (43.2%)    7 (15.9%)     
  **R**                          R0                213 (44.7%)            218 (45.8%)   45 (9.5%)    0.948
                                 R1/R2             41 (44.1%)             44 (47.3%)    8 (8.6%)      
  **Neoadjuvant chemotherapy**   yes               161 (43.6%)            179 (48.5%)   29 (7.9%)    0.135
                                 no                93 (46.5%)             83 (41.5%)    24 (12.0%)    
  **Clinical response**          Responder         44 (41.9%)             52 (49.5%)    9 (8.6%)     0.885
                                 Nonresponder      117 (44.5%)            126 (47.9%)   20 (7.6%)     
  **TRG**                        1a,1b             44 (42.3%)             53 (51.0%)    7 (6.7%)     0.783
                                 2,3               116 (44.1%)            125 (47.5%)   22 (8.4%)     

AEG = adenocarcinoma of the esophagogastric junction, GC = gastric cancer, TRG = tumor regression grade.

###### 

Genotype frequencies: MTHFR A1298C

                                                   **     MTHFR A1298C**                              **p**
  ------------------------------ ----------------- ----------------------- ------------- ------------ -------
  **All patients**                                 244 (42.9%)             268 (47.1%)   54 (9.5%)     
  **Status**                     Alive             152 (45.1%)             149 (44.2%)   36 (10.7%)   0.162
                                 Dead              92 (40.2%)              119 (52.0%)   18 (7.9%)     
  **Sex**                        Male              184 (43.0%)             204 (47.1%)   40 (9.3%)    0.945
                                 Female            60 (43.5%)              64 (46.4%)    14 (10.1%)    
  **Localization**               AEG               152 (43.7%)             164 (47.1%)   32 (9.2%)    0.793
  **UICC 7th edtition**          Gastric cancer    87 (41.0%)              103 (48.6%)   22 (10.4%)    
  **Localization**               AEG I             60 (42.6%)              68 (48.2%)    13 (9.2%)    0.968
  **UICC 6th edition**           AEG II/III + GC   184 (43.3%)             200 (47.1%)   41 (9.6%)     
  **Laurén**                     Intestinal        140 (44.0%)             150 (47.2%)   28 (8.8%)    0.835
                                 Non-intestinal    100 (42.9%)             109 (46.8%)   24 (10.3%)    
  **Grading**                    Low grade         70 (42.4%)              77 (46.7%)    18 (10.9%)   0.76
                                 High grade        172 (43.8%)             186 (47.3%)   35 (8.9%)     
  **pT**                         pT0               16 (42.1%)              18 (47.4%)    4 (10.5%)    0.701
                                 pT1               17 (33.3%)              28 (54.9%)    6 (11.8%)     
                                 pT2               119 (43.3%)             125 (45.5%)   31 (11.3%)    
                                 pT3               83 (45.4%)              88 (48.1%)    12 (6.6%)     
                                 pT4               9 (47.4%)               9 (47.4%)     1 (5.3%)      
  **pN**                         pN0               98 (40.7%)              118 (49.0%)   25 (10.4%)   0.654
                                 pN1               97 (48.5%)              84 (42.0%)    19 (9.5%)     
                                 pN2               30 (41.1%)              37 (50.7%)    6 (8.2%)      
                                 pN3               9 (32.1%)               16 (57.1%)    3 (10.7%)     
                                 pNx               10 (41.7%)              13 (54.2%)    1 (4.2%)      
  **pM**                         pM0               226 (43.3%)             244 (46.7%)   52 (10.0%)   0.402
                                 pM1               18 (40.9%)              24 (54.5%)    2 (4.5%)      
  **R**                          R0                199 (42.0%)             226 (47.7%)   49 (10.3%)   0.239
                                 R1/R2             45 (48.9%)              42 (45.7%)    5 (5.4%)      
  **Neoadjuvant chemotherapy**   Yes               156 (42.6%)             179 (48.9%)   31 (8.5%)    0.4
                                 No                88 (44.0%)              89 (44.5%)    23 (11.5%)    
  **Clinical response**          Responder         46 (43.8%)              49 (46.7%)    10 (9.5%)    0.812
                                 Nonresponder      109 (41.9%)             130 (50.0%)   21 (8.1%)     
  **TRG**                        1a,1b             41 (39.4%)              55 (52.9%)    8 (7.7%)     0.628
                                 2,3               114 (43.8%)             123 (47.3%)   23 (8.8%)     

AEG = adenocarcinoma of the esophagogastric junction, GC = gastric cancer, TRG = tumor regression grade.

Genotypes and survival
----------------------

### Survival and type of treatment

Survival analysis was conducted for the whole study cohort as well as for neoadjuvantly and primarily resected patients separately. The MTHFR C677T polymorphisms did not show a statistically significant influence on survival times in all patients (p = 0.412) nor in any analyzed subgroup (in neoadjuvantly treated patients p = 0.745, in primarily resected patients p = 0.295), although there was a slight trend for shorter survival of patients with the CC genotype (54.1 months median in patients with CC genotype versus 82.7 months in patients with CT and TT genotype, p = 0.237), Table [4](#T4){ref-type="table"}a.

###### 

Survival according to the individual genotypes

                                                **n**   **MS (months)**   **p**   **HR (95% CI)**
  ----------------------------------- --------- ------- ----------------- ------- ------------------
  a: All patients                                                                  
  **MTHFR C677T**                     CC        254     54.1              0.412    
                                      CT        262     82.7                      0.88 (0.67-1.15)
                                      TT        53      n.r.                      0.75 (0.46-1.22)
                                      CC        254     54.1              0.237    
                                      CT + TT   315     82.7                      0.86 (0.66-1.11)
  **MTHFR A1298C**                    AA        244     82.7              0.036    
                                      AC        268     47.1                      1.31 (1.0-1.72)
                                      CC        54      74.2                      0.77 (0.47-1.28)
                                      AC        268     47.1              0.016    
                                      AA + CC   301     82.7                      0.73 (0.56-0.94)
                                                **n**   **MS (months)**   **p**   **HR (95% CI)**
  b: Neoadjuvantly treated patients                                                
  **MTHFR C677T**                     CC        161     55.4              0.745    
                                      CT        179     82.7                      0.98 (0.7-1.38)
                                      TT        29      n.r.                      0.77 (0.4-1.51)
                                      CC        161     55.4              0.77     
                                      CT + TT   208     82.7                      0.95 (0.69-1.32)
  **MTHFR A1298C**                    AA        156     101.9             0.063    
                                      AC        179     47.1                      1.43 (1.02-2.01)
                                      CC        31      74.2                      0.85 (0.44-1.67)
                                      AC        179     47.1              0.02     
                                      AA + CC   190     101.9                     0.68 (0.49-0.94)
                                                **n**   **MS (months)**   **p**   **HR (95% CI)**
  c: Primarily resected patients                                                   
  **MTHFR C677T**                     CC        93      54.1              0.295    
                                      CT        83      n.r.                      0.72 (0.45-1.15)
                                      TT        24      66.0                      0.69 (0.34-1.4)
                                      CC        93      54.1              0.119    
                                      CT + TT   107     66.0                       
  **MTHFR A1298C**                    AA        88      66.0              0.366    
                                      AC        89      47.6                      0.16 (0.74-1.82)
                                      CC        23      62.2                      0.68 (0.31-1.46)
                                      AC        89      47.6              0.295    
                                      AA + CC   111     66.0                      0.79 (0.52-1.22)

In contrast, the MTHFR A1298C polymorphisms were prognostically relevant (p = 0.036) in all patients. The AC genotype was associated with a worse outcome compared to AA and CC. As we did not find a prognostic difference between the AA and CC genotype, the two homozygous genotypes were combined and analyzed together: 47.1 months median for AC genotype versus 82.7 months for AA/CC genotype, p = 0.016, see Table [4](#T4){ref-type="table"}a. The prognostic effect of MTHFR A1298C might be caused by the neoadjuvant treatment as it could not be shown in primarily resected patients.

The survival of the neoadjuvantly treated and primarily resected patients are presented in detail in Table [4](#T4){ref-type="table"}b and c. In neoadjvuantly treated patients the A1298C polymorphisms showed a survival benefit for the AA and CC genotypes, compared to the AC genotype (p = 0.02). In primarily resected patients the polymorphisms of both gene loci were not different in survival.

### Survival in respect of tumor localization

Furthermore, the association of the respective genotypes with prognosis was tested stratified for the different tumor localizations. In primarily resected patients we found no correlation between MTHFR polymorphisms and prognosis for the different localizations. In neoadjuvantly treated patients both polymorphisms had no prognostic impact in adenocarcinomas of the esophagus (AEG I) nor if taken all junctional tumors (AEG I, II, III) together according to the UICC 7^th^ classification. This is in contrast to patients with adenocarcinoma of the stomach: according to the old classification (gastric cancer including AEG II, III, UICC 6^th^) (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}) as well as in gastric cancer according to the new classification (gastric cancer without AEG II, III, UICC 7^th^) the MTHFR A1298C polymorphism was a prognostic factor (p = 0.005 and 0.009 respectively), (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). The AC genotype had a significantly worse prognosis compared to the rest in gastric cancer defined by the UICC6^th^ (p = 0.001, HR 2.0 (1.3-3.0)) and the UICC 7^th^ (p = 0.003, HR 2.8 (1.5-5.7)).

![**Survival in gastric cancer patients according to UICC 6th edition, MTHFR A1298C.** Legend: Subgroup analysis for patients with adenocarcinoma of the esophagogastric junction type II, III and stomach dependent on polymorphisms of MTHFR A1298C. Median Survival times: AA 101.9 months, CC 74.2 months, AC 35.0 months, p = 0.005.](1471-2407-14-58-2){#F2}

![**Survival in gastric cancer patients according to UICC 6th edition, MTHFR A1298C AC versus AA/CC.** Legend: Subgroup analysis for patients with adenocarcinoma of the esophagogastric junction type II, III and stomach dependent on polymorphisms of MTHFR A1298C, comparing AC genoytpe to AA and CC genotype. Median Survival times: AA/CC 82.7 months, AC 35.0 months, p = 0.001).](1471-2407-14-58-3){#F3}

![**Survival in gastric cancer patients according to UICC 7th edition, MTHFR A1298C.** Legend: Subgroup analysis for patients with adenocarcinoma of the stomach dependent on polymorphisms of MTHFR A1298C. Median Survival times: AA 82.7 months, CC not reached, AC 26.5 months, p = 0.009.](1471-2407-14-58-4){#F4}

![**Survival in gastric cancer patients according to UICC 7th edition, MTHFR A1298C AC versus AA/CC.** Legend: Subgroup analysis for patients with adenocarcinoma of the stomach dependent on polymorphisms of MTHFR A1298C, comparing AC genoytpe to AA and CC genotype. Median Survival times: AA/CC not reached, AC 26.5 months, p = 0.002.](1471-2407-14-58-5){#F5}

Multivariate analysis
---------------------

In neoadjuvantly treated gastric cancer patients according to UICC 6^th^ edition multivariate analysis (forward proportional hazard model) (including the univariate significant factors grading, pT-, pN-category, R-category, clinical and histopathological response, MTHFR A1298C polymorphisms as well as gender and age for adjustment) revealed pT-category (p = 0.002), R-category (p = 0.001), clinical response (p = 0.026) and MTHFR A1298C (p = 0.01) as independent prognostic factors. In gastric cancer patients according to UICC 7^th^ edition (including grading, pT-category, R-category, clinical response and MTHFR A1298C polymorphisms as well as gender and age) R-category (p = 0.001), clinical response (p = 0.021) and MTHFR A1298C (p = 0.028) were identified as independent prognostic factors (Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}). All prognostic factors were confirmed by the backward proportional hazard model.

###### 

Multivariate analysis in neoadjuvantly treated patients with gastric cancer including AEG II, III (UICC 6th)

                                 **HR**   **95% CI**   **p**
  ----------------------- ------ -------- ------------ -------
  **pT**                  pT0    1.00                  0.002
                          pT1    2.16     0.2-20.8      
                          pT2    5.10     0.7-37.5      
                          pT3    9.80     1.3-74.3      
                          pT4    14.50    1.7-122.9     
  **R**                   R0     1.00                  0.001
                          R1/2   2.20     1.3-3.5       
  **Clinical response**   yes    1.00                  0.026
                          no     2.10     1.1-4.2       
  **MTHFR A1298C**        AA     1.00                  0.01
                          AC     2.00     1.3-3.2       
                          CC     1.49     0.7-3.3       

###### 

Multivariate Analysis in neoadjuvantly treated patients with gastric cancer without AEG II, III (UICC 7th)

                                 **HR**   **95% CI**   **p**
  ----------------------- ------ -------- ------------ -------
  **R**                   R0     1.00                  0.001
                          R1/2   3.40     1.7-6.8       
  **Clinical response**   yes    1.00                  0.021
                          no     10.30    1.4-75.5      
  **MTHFR A1298C**        AA     1.00                  0.028
                          AC     2.80     1.3-5.9       
                          CC     2.00     0.5-7.6       

Discussion
==========

Our study revealed the AC genotype of the MTHFR A1298C as a predictor of poor prognosis in patients with gastric cancer. However, this genotype was only a prognostic marker after neoadjuvant treatment not in primarily resected patients. This gives a clear hint towards the contribution of the chemotherapy on the prognostic impact of this polymorphism. Additionally the prognostic influence seems to be limited to gastric cancer (UICC 6^th^ or 7^th^ edition) since it was not apparent for adenocarcinomas of the esophagus.

Both examined MTHFR polymorphisms are known to be functionally relevant. The variants (CT and TT) of MTHFR C677T polymorphisms are associated with decreased activity of MTHFR, which results in higher homocystein levels and lower plasma folate levels \[[@B42],[@B43]\]. Similarly, the A1298C variants (AC and CC) are associated with a lower enzyme activity, but results in literature are less final and conclusive than for C677T \[[@B31],[@B32],[@B44]\]. Our findings on MTHFR C677T are not statistically significant, but the trend for longer survival of the variants of C677T (CT and TT) would be in line with the functional hypothesis.

Furthermore MTHFR is thought to play an important role in response to fluoropyrimidine containing chemotherapy. A decreased activity of MTHFR results in higher 5,10-methylene tetrahydrofolate levels which leads to inhibition of thimidylate synthase and consequently to DNA damage \[[@B45]-[@B47]\] leading theoretically to an increased response and survival. This simplified theoretical approach cannot be confirmed by our data. Our results are in part conflicting, which points out the complexity of chemotherapy response and prognosis. Both seem to be affected by multiple pathways and related polymorphisms. In our study the AC variant of MTHFR A1298C is neither associated with response nor with improved outcome, but with poor prognosis in the subgroup of neoadjuvantly treated patients. However there exists data in literature, which correspond to our findings on the MTHFR A1298C polymorphism. Locally advanced adenocarcinoma of the stomach treated with cisplatin and 5-FU based chemotherapy with the variants of MTHFR A1298C (AC, CC) were associated with higher risks of recurrence and death in gastric cancer patients in a recent paper from our group \[[@B23]\] including 244 identical patients. Another study including unresectable, advanced gastric carcinomas reported similar results with shorter survival times of A1298C variants (AC and CC) (6.6 months median survival versus 18.5 months of the wild type (AA), p = 0.001) \[[@B48]\]. A pathway driven approach including amongst others both MTHFR polymorphisms showed conflicting results for esophageal cancer compared to ours. Longer survival and recurrence-free survival times could be shown for the MTHFR A1298C variants types (p = 0.01) as well as for combination of variant alleles at both loci (AC + CC) compared to the individuals with one wild type allele (AA) \[[@B49]\]. Two other studies reported a survival benefit for the TT variant of C677T \[[@B28],[@B50]\] in patients with fluorouracil-based chemotherapy. In the adjuvant setting the CC genotype of MTHFR C677T was associated with shorter recurrence-free survival (p = 0.031) \[[@B28]\]. However, several other studies could not show any prognostic impact of one the MTHFR polymorphisms for patients with esophagogastric cancer \[[@B22],[@B51]-[@B53]\], so that results remain controversial (see Table [7](#T7){ref-type="table"}).

###### 

MTHFR polymorphisms in literature

  **Author**            **Year**   **Polymorphism**   **n**   **Treatment**   **Tumor entity**   **Response (p-value)**   **Prognosis (p-value)**   **Genotypes**    **In P F**
  --------------------- ---------- ------------------ ------- --------------- ------------------ ------------------------ ------------------------- ---------------- ------------
  Ott \[[@B22]\]        2006       MTHFR C677T        235     neo CTx 135     AEGII/III/GC       0.14                     0.14                                        
                                                              OP 103          AEGII/III/GC       \-                       0.23                                        
  Ott \[[@B23]\]        2011       MTHFR C677T        258     neo CTx         AEGI 114           n.s.                     n.s.                                        
                                                                              AEGII-GC 144       n.s.                     n.s.                                        
                                   MTHFR A1298C       258     neo CTx         AEGI 114           n.s.                     n.s.                                        
                                                                              AEGII-GC 144       n.s.                     0.02                      AA \> CC \> AC   yes
  Huang \[[@B28]\]      2008       MTHFR C677T        116     adj CTx         GC                                          0.04                      TT/CT \> CC      0.056
  Wu \[[@B49]\]         2006       MTHFR C677T        210     neoCTx/RCTx     AEGI 174/SCC 36    n.a.                     n.s.                                        
                                   MTHFR A1298C       210     neoCTx/RCTx     AEGI 174/SCC36     n.a.                     0.011                     AC/CC \> AA      n.a.
  Ruzzo \[[@B51]\]      2006       MTHFR C677T        175     pall CTx        GC                 0.2                      n.s.                                        
  Chen \[[@B48]\]       2010       MTHFR A1298C       16/73   pall CTx        GC                 \-                       \<0.001                   AA \> AC/CC      n.a.
  Lu \[[@B54]\]         2004       MTHFR C677T        75      pall CTx        GC                 0.001                    \-                        TT \> CC/CT      \<0.001
  Goekkurt \[[@B52]\]   2009       MTHFR C677T        134     pall CTx        AEG/GC             0.214                    0.319                                       
                                   MTHFR A1298C       134     pall CTx        AEG/GC             0.053                    0.524                                       
  Goekkurt \[[@B55]\]   2006       MTHFR C677T        52      pall CTx        GC                 0.099                    n.s.                                        
  Shitara \[[@B50]\]    2010       MTHFR C677T        132     pall CTx        GC                 n.a.                     0.039                     TT \> CC/CT       
  Lee \[[@B53]\]        2005       MTHFR C677T        40      adj CTx         GC                                          0.90                                        

neo = neoadjuvant, CTx = chemotherapy, RCTx = radiochemotherapy, OP = primarily resected, adj = adjuvant, pall = palliative, AEG = adenocarcinoma of the esophagus/esophagusgastric junction, GC = gastric cancer, n.s. = not significant, n.a. = not applied, In P F = independent prognostic factor.

As in our previous published studies \[[@B16],[@B22],[@B23]\] we could not show an association between the two polymorphisms and response to neoadjuvant treatment. Most of the studies on MTHFR polymorphisms and upper gastrointestinal cancer could not reproduce the association of response with fluoropyrimidine based chemotherapy having been described for other cancer types, mainly advanced colon carcinoma \[[@B45],[@B56],[@B57]\], apart from one Chinese study for the TT genotype of the MTHFR C677T polymorphism and response \[[@B54]\].

In one study including metastatic gastroesophageal adenocarcinomas, the AC variant of MTHFR A1298C was associated with lower response rates (27% responder in contrast to 48 and 46% responder for AA and CC genotype, p = 0.053) \[[@B52]\]. Other studies could not confirm the effect of MTHFR C677T and A1298C variants in response to chemotherapy \[[@B22],[@B23],[@B51]\] (see Table [7](#T7){ref-type="table"}).

The conflicting and heterogenous findings highlight the demand on comprehensive pathway-based approaches for the prediction of response and prognosis by genetic polymorphisms as a potentially more successful and promising strategy. Beside the activity of the MTHFR, also the individual folate intake might influence outcome. Individuals with a high dietary folate intake are described to have a lower risk of developing gastrointestinal cancer. Consequently not only MTHFR polymorphisms, which play an important role in folate metabolism but also folate intake could be associated with prognosis in patients with esophagogastric carcinoma \[[@B50]\].

Further general problems of the presented studies are their heterogeneity and lack of comparability with respect to the number of patients included, inclusion criteria (type of tumor, tumor stage), different treatment concepts (palliative treatment versus curative treatment including radical surgery) and different genotypes. The change from UICC 6^th^ to 7^th^ might especially complicate the comparability of old and recent studies, as AEG II and III are classified differently \[[@B58]\]. To exclude this bias we repeated the analyses for both classifications and could show that in patients with AEG I or adenocarcinomas of the esophagogastric junction, the MTHFR polymorphisms did not have prognostic impact related to our recent paper \[[@B23]\].

Our study has some limitations. The first limitation is the inclusion of patients, on which we already reported recently, however, the follow-up was significantly extended \[[@B22],[@B23]\]. Secondly it is a retrospective exploratory study and therefore has the typical disadvantages of this study type.

But in contrast to many other studies, we analyzed patients being primarily resected without perioperative concepts to evaluate the prognostic impact of the described polymorphisms apart from response to chemotherapy as a simple prognostic factor. In our study the prognostic impact of MTHFR A1298C could not be demonstrated in primarily resected patients. This leads to the conclusion that response to treatment plays an important role for influence on survival of the different genotypes, despite the effect on response could not be measured by a correlation with clinical and histopathological response in this study. A further strength of our study is the relatively high number of patients, to our knowledge the largest published series, the inclusion of adenocarcinomas only and a homogenous 5-FU containing preoperative treatment followed by resection.

Conclusions
===========

The AC genotype of the MTHFR A1298C was associated with a poor prognosis in neoadjuvantly treated gastric cancer patients, although there was no association with clinically or histopathologically assessed response to chemotherapy. This gives a clear hint towards the modulation of prognosis by chemotherapy, which cannot be measured by the available methods of response evaluation. Large patient numbers and pathway driven approaches seem necessary to evaluate the prognostic impact of polymorphisms in patients with esophagogastric adenocarcinomas to tailor treatment in the future.
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